Lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) enhance the hydrolysis of triglycerides (TG) transported by chylomicron (CM) and very-low-density lipoprotein (VLDL). We report a case of severe hyperchylomicronemia with high levels of remnant lipoprotein and total cholesterol (T-Chol) in a 15-year-old boy. Precise examination of the lipid profile showed decreased activities of both LPL and HTGL, although the protein mass for LPL and HTGL were maintained. In addition, bezafibrate treatment effectively ameliorated hypertriglyceridemia in this case. This is the first case of hyperchylomicronemia with decreased activities and unaffected protein masses for both LPL and HTGL, without overt immuno-dysfunction.
Introduction
Type I hyperlipoproteinemia is characterized by massive hypertriglyceridemia with hyperchylomicronemia. Primary hyperchylomicronemia is mainly caused by lipoprotein lipase (LPL) deficiency or ApoC-II deficiency and is clinically important risk factor of pancreatitis. LPL promotes the hydrolysis of triglycerides (TG) transported by chylomicron (CM) and very-low-density lipoprotein (VLDL) (1, 2) . Humans lacking LPL or apolipoprotein C-II (ApoC-II), develop massive hypertriglyceridemia due to the accumulation of both CM and large VLDL (3) . A few cases of primary hyperchylomicronemia have been shown due to anti-LPL antibody or inhibitor (4) (5) (6) (7) (8) (9) .
Remnant lipoprotein is considered to be one of the risk factors for atherosclerosis (10) . Dietary lipids are absorbed in the intestine and converted to CM. Sequentially, LPL catalyzes the hydrolysis of TG in CM and CM-remnants are taken into hepatocytes via a remnant receptor. Deficiency or mutation of ApoE typically causes the high level of CMremnants because the hepatic remnant receptor recognizes ApoE located on the surface of CM-remnants. VLDL is produced in hepatocytes, secreted into the bloodstream, and converted to VLDL remnants by LPL. Hepatic triglyceride lipase (HTGL) promotes the hydrolysis of TG in VLDLremnants, as well as intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) (11) . HTGL deficiency thus results in the elevation of cholesterol and TG with impaired clearance of VLDL remnants (12) . We here first report a case of severe hyperchylomicronemia with high levels of remnant lipoprotein and total choles- 
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terol (T-Chol) in a 15-year-old boy, associated with significantly low activities for both LPL and HTGL.
Case Report
A 15-year-old boy presented with the chief complaint of generalized skin eruption and was admitted to the regional clinic. He was first treated with statin because of severe dyslipidemia (T-Chol 508 mg/dL, TG 1574 mg/dL), but statin treatment had no effect on lipid data. He was thus transferred to our hospital. The patient had no past medical or drinking history. His father had mild dyslipidemia [T-Chol 218 mg/dL, TG 286 mg/dL, low-density lipoproteincholesterol (LDL-C) 134 mg/dL, high-density lipoproteincholesterol (HDL-C) 41 mg/dL].
On admission, he had a normal constitution and was slightly obese (height: 171 cm; weight: 75 kg). The clinical findings on admission included eruptive xanthoma on bilateral back (Fig. 1A) , arm, and femur. A punch biopsy specimen taken from an eruption on his right back showed the appearance of numerous foam cells and the infiltration of inflammatory cells (lymphocytes) in the dermis (Fig. 1B) . These histologic features were compatible with xanthoma. On laboratory tests at admission (Table 1) , the patient had severe dyslipidemia: T-Chol 632 mg/dL, TG 1696 mg/dL, HDL-C 29 mg/dL. Apolipoprotein fractions of B, C, and E were elevated as shown in Table 1 . Apolipoprotein E isoform pattern of the patient was E3/E3, which is considered to be wild-type. When a serum sample was left to stand overnight, whole serum was turbid and the upper layer consisted of a creamy substance ( Fig. 2A) . On the polyacrylamide gel electrophoresis (PAGE) of whole serum, the pattern of increase in VLDL and IDL was observed (Table 1 and Fig. 2B ). Next, his serum sample was subjected to lipoprotein fractionation by ultracentrifugation and each of fractions was analyzed by agarose gel electrophoresis and measured T-Chol and TG contents ( Fig. 2C and 2D ). Signals of CM and VLDL were increased and the corresponding signals showed a broad pattern, suggesting the increase of CMand VLDL-remnants (Fig. 2C) . TG contents were elevated in IDL, LDL, and HDL fractions (Fig. 2D) .
Levels of LPL and HTGL were examined by using the post-heparin plasma (Table 2 ). LPL and HTGL were purified by affinity chromatography on heparin-Sepharose and these lipase activities were measured as described previously (13) . Briefly, the fraction eluted with 0.7 M NaCl was used as HTGL, and that eluted with 1.5 M NaCl was used as LPL. LPL activity was low while LPL mass was normal. Similarly, HTGL activity was decreased whereas HTGL mass was normal. Search for LPL gene mutation was performed after receiving the informed consent from the patient and his parents. The LPL gene comprises 10 exons encoding 448 amino acids. 126 cases of LPL gene mutation have been reported and LPL deficiency was caused among 89 cases in LPL gene mutation (Human Gene Mutation Database 2009.4). The majority of disease-causing mutations of LPL gene have been isolated to exons 3 to 6. The patient had no mutations in exons 3 to 6 of LPL gene. After hospitalization, he was treated with a fat-restricted diet and received nutritive education (Fig. 3) . The patient was discharged under the dietetic prescription (1800 kcal/ day, 25 g of fat/day) on the 23rd hospital day. On the 18th day after discharge, he suffered abdominal pain and subfever, and was hospitalized in the regional hospital. Abdominal CT showed pancreatic swelling and fluid collection around the pancreas (Fig. 4) . He was diagnosed with severe acute pancreatitis and began to be treated with protease inhibitors and antibiotics under fasting. On admission at the regional hospital, his lipid profile was aggravated (T-Chol 996 mg/dL, TG 6810 mg/dL) and he was transferred to our hospital on the 4th day of regional hospital. The patient continuously received the treatment for pancreatitis and recovered. After the 2nd admission to our hospital, the patient continuously received treatment for pancreatitis. However, TG levels were gradually increased even under fasting (TG levels; 506 mg/dL on day 6, 1149 mg/dL on day 9, 1309 mg/dL on day 12) and thus bezafibrate administration (400 mg/day) was started on day 12. On day 16, TG levels were decreased to 448 mg/dL and pancreatitis was recovered, and thus diet was orally started for this patient under calorie and fat restriction. Total calorie and fat content in diet were gradually increased while TG concentrations were maintained around from 400 to 700 mg/dL under bezafibrate treatment (TG levels; 593 mg/dL on day 19, 725 mg/dL on day 21, 422 mg/dL on day 26). However, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were elevated and thus bezafibrate treatment was suspended from day 26 (AST 183 U/L and ALT 143 U/L). TG concentrations tended to increase (TG levels; 510 mg/dL on day 30) and, AST and ALT levels were decreased (AST 110 U/L and ALT 98 U/L on day 32) after interruption of bezafibrate. On day 32, therefore, bezafibrate treatment (200 mg/day) was started again and finally this patient was treated with bezafibrate at 400 mg/day from day 37. Such bezafibrate administration gradually reduced TG levels (TG levels; 939 mg/dL on day 34, 482 mg/dL on day 37, 369 mg/dL on day 40) again and he was discharged under the treatment of bezafibrate (400 mg/day) and the dietetic prescription (1600 kcal/day, 20 g of fat/day) on day 41.
Discussion
We herein report the first case of severe hyperchylomicronemia with high levels of remnant lipoprotein and T-Chol Table 2 . HTGL-deficiency is a rare disease and is featured by high levels of T-Chol, TG, and HDL-C, and elevation of apolipoprotein A-I. LPL deficiency is characterized by severe hypertryglyceridemia and low HDL-C with normal level of T-Chol. This patient was also analyzed for gene mutations of LPL in exons 3 to 6, but no LPL gene mutation was detected. However, in this case, we could not exclude LPL gene mutations in other exons. Hyperchylomicronemia is also observed in subjects with diabetes and hypothyroidism, and in heavy drinkers, but such secondary hyperchylomicronemia was ruled out in this case. Consequently, the phenotype of our case differed from the typical LPL or HTGL deficiency. This case exhibited the low activities of both LPL and HTGL whereas LPL and HTGL masses were maintained (Table 2) , which suggest a novel type I hyperlipoproteinemia. Such reduction of LPL and HTGL activities may cause the complex lipid profile of this case. Interestingly, bezafibrate treatment effectively ameliorated hypertriglyceridemia in this case.
To explain the etiology of this case, there is a possibility of the existence of autoantibodies or inhibitors against LPL and HTGL. The concept of autoimmune dyslipidemia was first proposed by Beaumont in 1970 (14, 15) . Several cases of acquired type I dyslipidemia have been described in the course of autoimmune disease, such as systemic lupus erythematosus (SLE) (4, 5) , idiopathic thrombocytopenic purpura and Graves' disease (6). Interestingly, Reichlin et al demonstrated that antibodies against LPL occurred in 47% of SLE patients and in a similar percentage of patients with polymyositis or systemic sclerosis while the prevalence of antibodies against LPL was less in patients with rheumatoid arthritis (RA) or Sjögren's syndrome (7) . They attributed the high risk for atherosclerosis in SLE patients to the hypertriglyceridemia caused by anti-LPL antibodies. Other groups have independently described similar results (16, 17) . On the other hand, type I dyslipidemia occurred in a few patients without obvious autoimmune disease (18, 19) . Pruneta et al reported the usefulness of immunosuppressive therapy with azathioprine and prednisolone for a type I dyslipidemic patient without autoimmune disease (18) . Their patient showed low LPL activity due to the existence of anti-LPL antibody in plasma. The LPL activity recovered presumably by the immunosuppressive therapy. There is another possibility to explain the decreased activities of LPL and HTGL in this case. Mice overexpressing ApoC-III exhibited hyperchylomicronemia by reducing affinity of lipases to TG-rich lipoproteins and by reducing ApoE via replacement of ApoC-III in TG-rich lipoproteins (20) . In this case, as shown in Table 1 , ApoC-III was increased, and thus there is a possibility that the high level of ApoC-III may reduce the lipase activity, although lipoprotein metabolism in mice is not entirely similar to humans. In a literature search, to date only two cases showing the reduced activities of both LPL and HTGL have been reported (6, 21) . Among the two cases, our group previously reported that hyperchylomicronemia in a 26-year-old woman with autoimmune disease was attributed to the presence of autoantibodies directed against both LPL and HTGL identified as IgA (6). Yoshimura et al reported that autoantibodies to both LPL and HTGL were responsible for hyperchylomicronemia in a pregnant woman (21) . In the present case, the apparent autoimmunity was not detected despite intensively exploration for autoimmune disease (data not shown).
Conclusion
We report the first case of hyperchylomicronemia with decreased activities and maintained protein mass of both LPL and HTGL, with no sign of immuno-dysfunction.
